Eli Lilly and Co (LLY)
332.83
+1.05 (+0.32%)
USD |
NYSE |
Oct 06, 09:39
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 316.25B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 45.69% |
| Valuation | |
| PE Ratio | 53.86 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.39 |
| Price to Book Value | 37.01 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.98 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.968 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 22.48% |
News
Headline
Wire
Time (ET)
Yahoo
10/06 07:46
PR Newswire
10/06 06:45
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/26/2022* | -- | Results | Q3 2022 | -- | 1.94 | -- | |
| 10/26/2022* | 09:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 1.25 | 1.71 | -26.75% | |
| 08/04/2022 | 09:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 04/28/2022 | -- | Results | Q1 2022 | 2.62 | 2.30 | 13.72% | |
| 04/28/2022 | 09:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/03/2022 | -- | Results | Q4 2021 | 2.49 | 2.51 | -0.67% | |
| 02/03/2022 | 09:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. |
| URL | https://www.lilly.com |
| Investor Relations URL | https://investor.lilly.com/ |
| HQ State/Province | Indiana |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Oct. 26, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 3.66 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.7777 |
| Yield to Sector | 0.619 |
| Yield to Industry | 0.309 |
| Last Dividend Amt. | 0.98 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Aug. 12, 2022 |
| Yield (TTM) | 1.14% |
| Forward Yield | 1.18% |
| Payout Ratio | 58.21% |
| Cash Payout Ratio | 66.93% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 05, 2022.
Fundamentals
| Revenue (TTM) | 29.07B |
| Total Expenses (TTM) | 20.40B |
| Net Income (TTM) | 5.692B |
| Total Assets (Quarterly) | 47.06B |
| Total Liabilities (Quarterly) | 38.40B |
| Shareholders Equity (Quarterly) | 8.545B |
| Cash from Operations (TTM) | 7.108B |
| Cash from Investing (TTM) | -2.473B |
| Cash from Financing (TTM) | -4.992B |
Ratings
Profile
Edit
| Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. |
| URL | https://www.lilly.com |
| Investor Relations URL | https://investor.lilly.com/ |
| HQ State/Province | Indiana |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Oct. 26, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 12, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LLY Tweets |